Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vB_EcoP-R4
- Development stage
- Preclinical
- Lead developer
- Precise Health
01
Overview
vB_EcoP-R4 is a bacteriophage (phage) that targets and lyses susceptible bacterial isolates, specifically *Escherichia coli*. It is utilized as a matched adjunct on Precise Health's precision antimicrobial platform, which analyzes the bacterial genome of resistant isolates to identify matching phages or other adjuncts (such as β-lactamase inhibitors or depolymerases) to restore antibiotic sensitivity. vB_EcoP-R4 is sourced from external phage banks and is intended for the treatment of drug-resistant bacterial infections, particularly carbapenem-resistant *E. coli*.
- Other names
- Escherichia phage vB_EcoP-R4vB_EcoP-R4 phage
Beyond the preview
Go deeper on vB_EcoP-R4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vB_EcoP-R4.